Baxter, Momenta form follow-on biologics collaboration; terminated
Baxter International Inc. and Momenta Pharmaceuticals Inc. (structural analysis of complex sugars) have agreed to develop and market as many as six follow-on biologics worldwide in multiple indications. Each partner has granted the other an exclusive license to its IP.
- Generic Drugs
- Large Molecule
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com